By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?
GeopoliticaOne-OffSalute e medicina3a
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoAvviso sulla qualità dei datiDati della fonte degradati
Dati al 26 ott 2026, 03:24 UTC · criterio pm-quality-4
Previsione della comunità attualeSì 53.5%
Previsori
5
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 1 ora fa
In ritardo18 nov 22, 02:41 UTC1 gen 30, 08:00 UTC
Trend
Regole
Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system.
- There's a list of major immune checkpoint inhibitors here: https://en.wikipedia.org/wiki/Checkpoint_inhibitor
- A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless.
- You can read an overview of the topic here: https://sci-hub.se/10.1093/annonc/mdw217
- This market resolves YES if any combination therapy is approved that:
- Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.
